Literature DB >> 34535859

COVID-19 and increasing demand for medical oxygen: can impurity be a problem?

Vivek Singh Malik1, Khaiwal Ravindra2, Meenu Singh3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34535859      PMCID: PMC8448390          DOI: 10.1007/s11356-021-16385-x

Source DB:  PubMed          Journal:  Environ Sci Pollut Res Int        ISSN: 0944-1344            Impact factor:   4.223


× No keyword cloud information.

Introduction

The COVID-19 pandemic in 2021 has accelerated the demand for oxygen supplies globally. Many countries have not seen such high demand before the pandemic to meet their daily oxygen requirement (Usher 2021). Worldwide, governments are scaling up their existing facilities to fill the oxygen demand. In the healthcare system, oxygen is an essential medicine required at all levels. It is estimated that 20–40% of deaths due to pneumonia could be prevented using oxygen therapy (WHO 2021). Medical air in hospital settings is widely used for mechanical ventilation, infant resuscitation, aerosol drug delivery, and neonatal environment control (Edwards et al. 2018). Oxygen cylinders, oxygen concentrators, liquid oxygen, and membrane separator oxygen enrichers are commonly used for oxygen therapy (Rees and Dudley 1998). In the current COVID-19 pandemic, long-term oxygen therapy is required at both hospitals and in-home settings that the respiratory physician should supervise for optimal treatment (Rees and Dudley 1998). Unprecedented production of oxygen and refilling of cylinders can give rise to the risk of impurities, which could lead to an increase in hidden mortality. However, it would be difficult to assess the increase in mortality due to the impurity of the oxygen gas. Hence, the purity of the oxygen needs to be regulated by the respective authorities (Edwards et al. 2018). Higher oxygen production can give rise to a possibility of contamination. In a recent study, the CO2 impurity was reported in oxygen cylinders above the recommended threshold level (Edwards et al. 2018). In previous studies, various health effects were reported due to the common air pollutants (WHO 2005). It was also observed that unintentional inhalation of NO in industrial regions might change the PaO2 (Benzing et al. 1999). Edwards et al. (2018) also mentioned onsite production of medical air poses a risk of raising the CO2 and NOx (nitric oxides) concentration above the United States Pharmacopeia (USP) threshold (Edwards et al. 2018). This rise of these trace gases may be due to the dryer that is used to capture the CO2 contaminant and humidity. Impurity sources can be arising due to the production and delivery systems, as well as from the environmental pollution levels near the regions. According to the FDA guidelines, medical gases should be checked for any adulteration during production, packaging, delivery, and manufacturing facilities (FDA 2015). Here, we would like to highlight few points for policymakers/local authorities (Table 1) and for the general public (Table 2) to create awareness and recommendations to improve the quality of oxygen.
Table 1

Interventions required by policymakers or local authorities

Monitor gas testing facilities, laboratories, and calibration facilities at the site
To ensure compliance and procedures of finished gas for its quality
Purity and grade (ultra-pure, 99.999% minimum) should be maintained
A random check of tankers and especially cylinders for chemical analysis of oxygen gases
Impurity parameters certificate should be provided for the levels (i.e., carbon monoxide/carbon dioxide, moisture, arsenic, oil, halogen, oxidizing substances, acidity or alkalinity, argon, hydrocarbons)
Test results can be cross-checked by the local authority for any foreign materials, moisture, and contaminants
To monitor any misuse of other cylinders (i.e., helium, hydrogen, acetylene, argon) for refilling oxygen without proper cleaning and conditioning
Monitoring for the sanitization of oxygen supply (pipeline and tubes) for unwanted fungal growth
Special attention should be given to test “black fungus” (mucormycosis) infection among recovered patients
Checking/advisory for black fungus on patients on oxygen support should be made an essential part of the COVID-19 control protocol at every level
Special attention/care should be given to comorbid and patients using the steroid to check the fungal infection for the hidden cause of death
Table 2

Recommendation/awareness needed for the general public

Oxygen gas cylinder should be kept at normal room temperature
Always use distilled water to make oxygen hydrated before use
Never use poor-quality water such as tap water, boiled water, or purified RO water
Masks, nasal cannulae should be cleaned and checked for any leakage by the attendee
If using an oxygen concentrator, attendee should adhere to manufacturer guidelines for proper cleaning as and when required
The oxygen concentrator should be placed in a well-ventilated and clean area
Oxygen filters should be properly cleaned from time to time
Avoid smoking (wood, cigarette, sticks) in any form, active or passive, near to oxygen concentrator
Attendee can monitor patient nostril for any black pigmentation, as soon as it is noticed even as the smallest spot contact doctor immediately for further treatment
Avoid irrational use of steroids without recommendations
Interventions required by policymakers or local authorities Recommendation/awareness needed for the general public Another reason for the increase in the COVID-19 mortality can also be due to the black fungus, which are present in the environment (Richardson 2009). This could lead to mucormycosis, which could be a fatal disease for people who have weakened immune systems (Spellberg et al. 2005). In the nasal tract, black fungus develop due to the poor quality of water used to hydrate the oxygen in a hospital setting (piped and cylinders). This fungus grows in the nostril, travels towards the eyes (Klotz et al. 2000), and then towards the brain, which can paralyze the nerves (Escobar and Del Brutto 1990), cause permanent damage to the eye, or even could lead to a heart attack (Naik et al. 2021; Jackman and Simonsen 1992). An evidence-based advisory for screening, diagnosis, and management of mucormycosis developed by Cornely et al. (2019) should be followed and need to be updated considering the recent evidence of mucormycosis in the COVID-19 pandemic (Cornely et al. 2019). In a hospital setting, constantly monitor distilled water for oxygen hydration before using it in oxygen therapy devices (Cahill and Heath 1990). Use of tap water even after boiling is not recommended in the humidifier as after some time; impurities (micro-metals and minerals/salts) start to buildup, leading to severe health issues even after using life-saving precious oxygen therapy. Globally, we are facing an emergency that needs support from authorities and the community to minimize the suffering and improve the well-being of all. In lower- and middle-income countries, oxygen purity can be a significant issue that requires local interventions at the earliest. Countries where there is prevalence of malaria, sepsis, pneumonia, and other ailments should also prioritize where oxygen therapy requires at large (Usher 2021).
  12 in total

Review 1.  Fungal and parasitic infections of the eye.

Authors:  S A Klotz; C C Penn; G J Negvesky; S I Butrus
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

Review 2.  Provision of oxygen at home.

Authors:  P J Rees; F Dudley
Journal:  BMJ       Date:  1998-10-03

3.  Medical oxygen crisis: a belated COVID-19 response.

Authors:  Ann Danaiya Usher
Journal:  Lancet       Date:  2021-03-06       Impact factor: 79.321

Review 4.  Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.

Authors:  Oliver A Cornely; Ana Alastruey-Izquierdo; Dorothee Arenz; Sharon C A Chen; Eric Dannaoui; Bruno Hochhegger; Martin Hoenigl; Henrik E Jensen; Katrien Lagrou; Russell E Lewis; Sibylle C Mellinghoff; Mervyn Mer; Zoi D Pana; Danila Seidel; Donald C Sheppard; Roger Wahba; Murat Akova; Alexandre Alanio; Abdullah M S Al-Hatmi; Sevtap Arikan-Akdagli; Hamid Badali; Ronen Ben-Ami; Alexandro Bonifaz; Stéphane Bretagne; Elio Castagnola; Methee Chayakulkeeree; Arnaldo L Colombo; Dora E Corzo-León; Lubos Drgona; Andreas H Groll; Jesus Guinea; Claus-Peter Heussel; Ashraf S Ibrahim; Souha S Kanj; Nikolay Klimko; Michaela Lackner; Frederic Lamoth; Fanny Lanternier; Cornelia Lass-Floerl; Dong-Gun Lee; Thomas Lehrnbecher; Badre E Lmimouni; Mihai Mares; Georg Maschmeyer; Jacques F Meis; Joseph Meletiadis; C Orla Morrissey; Marcio Nucci; Rita Oladele; Livio Pagano; Alessandro Pasqualotto; Atul Patel; Zdenek Racil; Malcolm Richardson; Emmanuel Roilides; Markus Ruhnke; Seyedmojtaba Seyedmousavi; Neeraj Sidharthan; Nina Singh; János Sinko; Anna Skiada; Monica Slavin; Rajeev Soman; Brad Spellberg; William Steinbach; Ban Hock Tan; Andrew J Ullmann; Jörg J Vehreschild; Maria J G T Vehreschild; Thomas J Walsh; P Lewis White; Nathan P Wiederhold; Theoklis Zaoutis; Arunaloke Chakrabarti
Journal:  Lancet Infect Dis       Date:  2019-11-05       Impact factor: 25.071

Review 5.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

Review 6.  The clinical manifestations of cardiac mucormycosis.

Authors:  J D Jackman; R L Simonsen
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

7.  Unintended inhalation of nitric oxide by contamination of compressed air: physiologic effects and interference with intended nitric oxide inhalation in acute lung injury.

Authors:  A Benzing; T Loop; G Mols; K Geiger
Journal:  Anesthesiology       Date:  1999-10       Impact factor: 7.892

8.  Multiple brain abscesses from isolated cerebral mucormycosis.

Authors:  A Escobar; O H Del Brutto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-05       Impact factor: 10.154

Review 9.  The ecology of the Zygomycetes and its impact on environmental exposure.

Authors:  M Richardson
Journal:  Clin Microbiol Infect       Date:  2009-10       Impact factor: 8.067

10.  Acute myocardial infarction secondary to mucormycosis after lung transplantation.

Authors:  Chetan A Naik; Susan K Mathai; Uriel S Sandkovsky; Kenneth A Ausloos; Joseph M Guileyardo; Gary Schwartz; David P Mason; Robert Gottlieb; Todd J Grazia
Journal:  IDCases       Date:  2020-12-09
View more
  1 in total

1.  Editorial Commentary on the Article "Neurological Disorders Seen During Second Wave of SARS-CoV-2 Pandemic from Two Tertiary Care Centers in Central and Southern Kerala".

Authors:  Lakshmi Narasimhan Ranganathan; S Kaushik; R Shrivarthan; Guhan Ramamurthy
Journal:  Ann Indian Acad Neurol       Date:  2022-05-25       Impact factor: 1.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.